Nexalin Technology, Inc.

Nexalin Technology, Inc. develops and commercializes non-invasive electrotherapy devices used in mental health and related therapeutic applications. The company sells devices, consumable supplies, and licensing or treatment-fee arrangements tied to customer use of its systems, with activity in the United States and overseas markets.

79,7 %

−2 725,8 %

+78,8 %

4.85

4.70

— Nexalin Technology, Inc.
%
Devices35% Electrotherapy systems sold for therapeutic use in clinical and other settings.
Equipment and Consumables40% Boards, electrodes, patient cables, and other hardware used with the device.
Licensing Fees15% Monthly licensing arrangements that allow customers to use the technology.
Treatment Fees and Supplies10% Usage-based treatment fees and recurring supply sales tied to installed systems.

Nexalin sells to customers that operate or distribute therapeutic devices, including healthcare-related users and...

  • Healthcare and therapeutic usersprimary

    Buy devices and related supplies for therapeutic use and ongoing patient treatments.

  • International equipment customersprimary

    Purchase boards, devices, and accessories for deployment outside the U.S.

  • License and treatment-fee customerssecondary

    Pay recurring fees for access to the technology and for each treatment performed.

The company serves customers in the United States and also sells devices and equipment overseas...

  • •United States is the core servicing market
  • •Overseas sales include devices and equipment
  • •China was a notable destination for board shipments
  • •Oman was cited for a prior device sale
  • •International mix can shift revenue by quarter

Nexalin’s strategy centers on expanding commercialization of its device platform, including overseas sales, while...

01
Commercialize overseas marketsshort-term

International sales provide a path to revenue while U.S. approval and reimbursement are developed.

02
Obtain U.S. approval and reimbursement supportmedium-term

U.S. market access and coverage are key to broader adoption in healthcare settings.

03
Protect intellectual property and product safetylong-term

Defending the technology and maintaining safety are central to competitive positioning and adoption.

Nexalin faces commercialization risk because adoption depends on regulatory approval, reimbursement, and competition...

critical

Going-concern and financing risk

The company has limited cash resources and has relied on equity funding to support operations.

Scope
Corporate liquidity
Materiality
high
high

Regulatory approval risk

U.S. device sales depend on obtaining and maintaining approval for the product.

Scope
U.S. market access
Materiality
high
high

Reimbursement and coverage risk

Healthcare adoption can be limited if payers do not cover the therapy adequately.

Scope
Healthcare commercialization
Materiality
high
high

Tariff and trade exposure

Imported components and exported products can be affected by tariffs or retaliatory trade actions.

Scope
China and other export markets
Materiality
high
medium

Competition from alternative therapies

Customers may choose other treatment modalities with stronger clinical or economic support.

Scope
Therapeutic device market
Materiality
medium
Revenue recognition across devices, licensing, and treatment fees
Affects reported revenue timing and quarterly comparability
Revenue mix and gross margin variability
Can move gross profit materially from period to period
Fair value changes on short-term investments
Affects comprehensive loss and equity
Going-concern assessment
Important for evaluating solvency and disclosure risk

IR-Med, Inc.

Electromedical & Electrotherapeutic Apparatus

NEXGEL, INC.

NXGL · Surgical & Medical Instruments & Apparatus

Neuronetics, Inc.

STIM · Surgical & Medical Instruments & Apparatus

Aclarion, Inc.

ACON · Services-Medical Laboratories

RetinalGenix Technologies Inc.

RTGN · Surgical & Medical Instruments & Apparatus

Solana Co

HSDT · Finance Services

: 29/04/2026